U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Approval Year

2003
181
Substance Class Protein
Created
by admin
on Mon Mar 31 20:47:24 GMT 2025
Edited
by admin
on Mon Mar 31 20:47:24 GMT 2025
Protein Type MONOCLONAL ANTIBODY
Protein Sub Type IGG1
Sequence Origin HUMANIZED MOUSE
Sequence Type COMPLETE
Record UNII
XX2MN88N5D
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
ANTI-CD11A
Preferred Name English
EFALIZUMAB
EMA EPAR   HSDB   INN   MART.   MI   USAN   VANDF   WHO-DD  
USAN   INN  
Official Name English
EFALIZUMAB [HSDB]
Common Name English
HU1124
Code English
HU-1124
Code English
EFALIZUMAB [USAN]
Common Name English
EFALIZUMAB [MI]
Common Name English
Efalizumab [WHO-DD]
Common Name English
IMMUNOGLOBULIN G1, ANTI-(HUMAN CD11A (ANTIGEN)) (HUMAN-MOUSE MONOCLONAL HU1124 .GAMMA.1-CHAIN), DISULPHIDE WITH HUMAN-MOUSE MONOCLONAL HU1124 LIGHT CHAIN, DIMER
Common Name English
EFALIZUMAB [VANDF]
Common Name English
EFALIZUMAB [EMA EPAR]
Common Name English
efalizumab [INN]
Common Name English
EFALIZUMAB [MART.]
Common Name English
IMMUNOGLOBULIN G1, ANTI-(HUMAN CD11A (ANTIGEN)) (HUMAN-MOUSE MONOCLONAL HU1124 .GAMMA.1-CHAIN), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL HU1124 LIGHT CHAIN, DIMER
Systematic Name English
Classification Tree Code System Code
WHO-ATC L04AA21
Created by admin on Mon Mar 31 20:47:24 GMT 2025 , Edited by admin on Mon Mar 31 20:47:24 GMT 2025
NDF-RT N0000175856
Created by admin on Mon Mar 31 20:47:24 GMT 2025 , Edited by admin on Mon Mar 31 20:47:24 GMT 2025
LIVERTOX NBK548791
Created by admin on Mon Mar 31 20:47:24 GMT 2025 , Edited by admin on Mon Mar 31 20:47:24 GMT 2025
EMA ASSESSMENT REPORTS RAPTIVA (WITHDRAWN: PSORIASIS)
Created by admin on Mon Mar 31 20:47:24 GMT 2025 , Edited by admin on Mon Mar 31 20:47:24 GMT 2025
NCI_THESAURUS C20401
Created by admin on Mon Mar 31 20:47:24 GMT 2025 , Edited by admin on Mon Mar 31 20:47:24 GMT 2025
NDF-RT N0000175856
Created by admin on Mon Mar 31 20:47:24 GMT 2025 , Edited by admin on Mon Mar 31 20:47:24 GMT 2025
NDF-RT N0000011174
Created by admin on Mon Mar 31 20:47:24 GMT 2025 , Edited by admin on Mon Mar 31 20:47:24 GMT 2025
NDF-RT N0000011174
Created by admin on Mon Mar 31 20:47:24 GMT 2025 , Edited by admin on Mon Mar 31 20:47:24 GMT 2025
NDF-RT N0000011174
Created by admin on Mon Mar 31 20:47:24 GMT 2025 , Edited by admin on Mon Mar 31 20:47:24 GMT 2025
NDF-RT N0000175856
Created by admin on Mon Mar 31 20:47:24 GMT 2025 , Edited by admin on Mon Mar 31 20:47:24 GMT 2025
WHO-VATC QL04AA21
Created by admin on Mon Mar 31 20:47:24 GMT 2025 , Edited by admin on Mon Mar 31 20:47:24 GMT 2025
NDF-RT N0000175858
Created by admin on Mon Mar 31 20:47:24 GMT 2025 , Edited by admin on Mon Mar 31 20:47:24 GMT 2025
Code System Code Type Description
RXCUI
356988
Created by admin on Mon Mar 31 20:47:24 GMT 2025 , Edited by admin on Mon Mar 31 20:47:24 GMT 2025
PRIMARY RxNorm
SMS_ID
100000089542
Created by admin on Mon Mar 31 20:47:24 GMT 2025 , Edited by admin on Mon Mar 31 20:47:24 GMT 2025
PRIMARY
CAS
214745-43-4
Created by admin on Mon Mar 31 20:47:24 GMT 2025 , Edited by admin on Mon Mar 31 20:47:24 GMT 2025
PRIMARY
INN
8122
Created by admin on Mon Mar 31 20:47:24 GMT 2025 , Edited by admin on Mon Mar 31 20:47:24 GMT 2025
PRIMARY
NCI_THESAURUS
C68831
Created by admin on Mon Mar 31 20:47:24 GMT 2025 , Edited by admin on Mon Mar 31 20:47:24 GMT 2025
PRIMARY
DRUG CENTRAL
4959
Created by admin on Mon Mar 31 20:47:24 GMT 2025 , Edited by admin on Mon Mar 31 20:47:24 GMT 2025
PRIMARY
HSDB
7847
Created by admin on Mon Mar 31 20:47:24 GMT 2025 , Edited by admin on Mon Mar 31 20:47:24 GMT 2025
PRIMARY
EVMPD
SUB20027
Created by admin on Mon Mar 31 20:47:24 GMT 2025 , Edited by admin on Mon Mar 31 20:47:24 GMT 2025
PRIMARY
MERCK INDEX
m4837
Created by admin on Mon Mar 31 20:47:24 GMT 2025 , Edited by admin on Mon Mar 31 20:47:24 GMT 2025
PRIMARY Merck Index
IUPHAR
6593
Created by admin on Mon Mar 31 20:47:24 GMT 2025 , Edited by admin on Mon Mar 31 20:47:24 GMT 2025
PRIMARY
WIKIPEDIA
EFALIZUMAB
Created by admin on Mon Mar 31 20:47:24 GMT 2025 , Edited by admin on Mon Mar 31 20:47:24 GMT 2025
PRIMARY
USAN
LL-74
Created by admin on Mon Mar 31 20:47:24 GMT 2025 , Edited by admin on Mon Mar 31 20:47:24 GMT 2025
PRIMARY
FDA UNII
XX2MN88N5D
Created by admin on Mon Mar 31 20:47:24 GMT 2025 , Edited by admin on Mon Mar 31 20:47:24 GMT 2025
PRIMARY
ChEMBL
CHEMBL1201575
Created by admin on Mon Mar 31 20:47:24 GMT 2025 , Edited by admin on Mon Mar 31 20:47:24 GMT 2025
PRIMARY
DRUG BANK
DB00095
Created by admin on Mon Mar 31 20:47:24 GMT 2025 , Edited by admin on Mon Mar 31 20:47:24 GMT 2025
PRIMARY
MESH
C472181
Created by admin on Mon Mar 31 20:47:24 GMT 2025 , Edited by admin on Mon Mar 31 20:47:24 GMT 2025
PRIMARY
From To
1_22 1_96
1_148 1_204
1_224 3_214
1_230 2_230
1_233 2_233
1_265 1_325
1_371 1_429
2_22 2_96
2_148 2_204
2_224 4_214
2_265 2_325
2_371 2_429
3_23 3_88
3_134 3_194
4_23 4_88
4_134 4_194
Related Record Type Details
INTEGRIN ALPHA-L
TARGET -> INHIBITOR
HIGH AFFINITY IMMUNOGLOBULIN GAMMA FC RECEPTOR I
TARGET -> AGONIST
Related Record Type Details
EFALIZUMAB
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Molecular Formula CHEMICAL
MOL_WEIGHT:ESTIMATED CHEMICAL
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966